Literature DB >> 31244412

Anticancer Triazenes: from Bioprecursors to Hybrid Molecules.

Ana P Francisco1, Eduarda Mendes1, Ana R Santos1, Maria J Perry1.   

Abstract

Triazenes are a very useful and diverse class of compounds that have been studied for their potential in the treatment of many tumors including brain tumor, leukemia and melanoma. Novel compounds of this class continue to be developed as either anticancer compounds or even with other therapeutic applications. This review focused on several types of triazenes from the simplest ones like 1,3-dialkyl-3-acyltriazenes to the more complex ones like combi-triazenes with an emphasis on how triazenes have been developed as effective antitumor agents. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Triazenes; alkylating agents; anticancer activity; aryltriazenes; combi-triazenes; hybrid molecules; prodrugs.

Mesh:

Substances:

Year:  2019        PMID: 31244412     DOI: 10.2174/1381612825666190617155749

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Novel sulphonamides incorporating triazene moieties show powerful carbonic anhydrase I and II inhibitory properties.

Authors:  Sinan Bilginer; Baris Gonder; Halise Inci Gul; Ruya Kaya; Ilhami Gulcin; Baris Anil; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

2.  Chemo- and regio-divergent access to fluorinated 1-alkyl and 1-acyl triazenes from alkynyl triazenes.

Authors:  Jin-Fay Tan; Carl Thomas Bormann; Kay Severin; Nicolai Cramer
Journal:  Chem Sci       Date:  2022-02-09       Impact factor: 9.825

3.  Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity.

Authors:  Qian Zhao; Shan-Shan Xiong; Can Chen; Hong-Ping Zhu; Xin Xie; Cheng Peng; Gu He; Bo Han
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.